Diagnostic accuracy of 123I-FP-CIT SPECT in diagnosing drug-induced parkinsonism: A prospective study;Utilidad de la tomografía por emisión de fotón simple con 123Ioflupano en el diagnóstico del parkinsonismo relacionado con fármacos. Estudio prospectivo

Neurologia

Volumn 28, Issue 5, 2013, Pages 276-282

  Olivares Romero, J ^a   Arjona Padillo, A ^a  

^a HOSPITAL TORRECÁRDENAS   (Spain)

Author keywords

Drugs; Iatrogenic parkinsonism; Neuroleptic agents; Prospective study; Single photon emission computed tomography with ioflupane (123I); Subclinical parkinsonism

Indexed keywords

IOFLUPANE I 123; NEUROLEPTIC AGENT;

ARTICLE; CLINICAL ARTICLE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE EXACERBATION; DRUG INDUCED DISEASE; HUMAN; IATROGENIC DISEASE; PARKINSONISM; PREDICTIVE VALUE; PRESCRIPTION; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOKINESIA; LIKELIHOOD FUNCTIONS; MALE; MIDDLE AGED; PARKINSON DISEASE, SECONDARY; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TROPANES;

EID: 84878536832     PISSN: 02134853     EISSN: 15781968     Source Type: Journal    
DOI: 10.1016/j.nrl.2012.05.005     Document Type: Article

References (32)

1. Thanvi B., Treadwell S. Drug induced parkinsonism: a common cause of parkinsonism in older people. J Postgrad Med 2009, 85:322-326.
2. Mena M.A., de Yébenes J.G. Drug-induced parkinsonism. Expert Opin Drug Saf 2006, 5:759-771.
3. Munhoz R.P., Werneck L.C., Teive H.A. The differential diagnoses of parkinsonism: findings from a cohort of 1528 patients and a 10 years comparison in tertiary movement disorders clinics. Clin Neurol Neurosurg 2010, 112:431-435.
4. López-Sendón J.L., Mena M.A., de Yébenes J.G. Drug-induced parkinsonism in the elderly: incidence, management and prevention. Drugs Aging 2012, 29:105-118.
5. Bondon-Guitton E., Perez-Lloret S., Bagheri H., Brefel C., Rascol O., Montastruc J.L. Drug-induced parkinsonism: A review of 17 years' experience in a regional pharmacovigilance center in France. Mov Disord 2011, 26:2226-2231.
6. Gershanik O.S. Drug-induced parkinsonism in the aged. Recognition and prevention. Drugs Aging 1994, 5:127-132.
7. Nguyen N., Pradel V., Micallef J., Montastruc J.L., Blin O. Drug-induced Parkinson syndromes. Therapie 2004, 59:105-112.
8. Hambye A.S., Vervaet A., Dethy S. SPECT FP-CIT. in clinically inconclusive Parkinsonian syndrome during amiodarone treatment: a study with follow-up. Nucl Med Commun 2010, 31:583-589.
9. Mahmoud F., Tampi R.R. Valproic acid-induced parkinsonism in the elderly: a comprehensive review of the literature. Am J Geriatr Pharmacother 2011, 9:405-412.
10. Jamora D., Lim S.H., Pan A., Tan L., Tan E.K. Valproate-induced Parkinsonism in epilepsy patients. Mov Disord 2007, 22:130-133.
11. Ghadirian A.M., Annable L., Bélanger M.C., Chouinard G. A cross-sectional study of parkinsonism and tardive dyskinesia in lithium-treated affective disordered patients. J Clin Psychiatry 1996, 57:22-28.
12. Martí Massó J.F., Martí I., Carrera N., Poza J.J., López de Munain A. Trimetazidine induces parkinsonism, gait disorders and tremor. Therapie 2005, 60:419-422.
13. Shannon KM. Trastornos del movimiento. En: Bradley, W.G., Daroff, R.B., Fenichel, G.M., Jankovic, J., editores., Neurología, clínica., IV, ed., Madrid, 2004. p. 2105-52.
14. Llau M.E., Nguyen L., Senard J.M., Rascol O., Montastruc J.L. Drug-induced parkinsonian syndromes: a 10-year experience at a regional center of pharmaco-vigilance. Rev Neurol (Paris) 1994, 150:757-762.
15. Stephen P.J., Williamson J. Drug-induced parkinsonism in the elderly. Lancet 1984, 2:1082-1083.
16. Shin H.W., Kim M.J., Kim J.S., Lee M.C., Chung S.J. Levosulpiride-induced movement disorders. Mov Disord 2009, 24:2249-2253.
17. Tinazzi M., Antonini A., Bovi T., Pasquin I., Steinmayr M., Moretto G., et al. Clinical and [123I]FP-CIT SPECT imaging follow-up in patients with drug-induced parkinsonism. J Neurol 2009, 256:910-915.
18. Lorberboym M., Treves T.A., Melamed E., Lampl Y., Hellmann M., Djaldetti R. [123I]-FP/CIT SPECT imaging for distinguishing drug-induced parkinsonism from Parkinson's disease. Mov Disord 2006, 21:510-514.
19. Díaz-Corrales F.J., Sanz-Viedma S., Garcia-Solis D., Escobar-Delgado T., Mir P. Clinical features and 123I-FP-CIT SPECT imaging in drug-induced parkinsonism and Parkinson's disease. Eur J Nucl Med Mol Imaging 2010, 37:556-564.
20. Esper C.D., Factor S.A. Failure of recognition of drug-induced parkinsonism in the elderly. Mov Disord 2008, 23:401-404.
21. Kägi G., Bhatia K.P., Tolosa E. The role of DAT-SPECT in movement disorders. J Neurol Neurosurg Psychiatry 2010, 81:5-12.
22. Vlaar A.M., de Nijs T., Kessels A.G., Vreeling F.W., Winogrodzka A., Mess W.H., et al. Diagnostic value of 123I-ioflupane and 123I-iodobenzamide SPECT scans in 248 patients with parkinsonian syndromes. Eur Neurol 2008, 59:258-266.
23. Lorenzo Bosquet C., Miquel Rodríguez F., Roca Bielsa I., Milà M., Aguadé Bruix S., Castell Conesa J. Differential diagnosis of parkinsonism using dopamine transporters brain SPECT. Med Clin (Barc) 2004, 122:325-328.
24. Lavalaye J., Linszen D.H., Booij J., Dingemans P.M., Reneman L., Habraken J.B., et al. Dopamine transporter density in young patients with schizophrenia assessed with [123]FP-CIT SPECT. Schizophr Res 2001, 47:59-67.
25. Booij J., Speelman J.D., Horstink M.W., Wolters E.C. The clinical benefit of imaging striatal dopamine transporters with [123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism. Eur J Nucl Med 2001, 28:266-272.
26. Tolosa E., Coelho M., Gallardo M. DAT imaging in drug-induced and psychogenic parkinsonism. Mov Disord 2003, 18(Suppl. 7):S28-S33.
27. Jennings D.L., Seibyl J.P., Oakes D., Eberly S., Murphy J., Marek K. (123I) beta-CIT and single-photon emission computed tomographic imaging vs clinical evaluation in Parkinsonian syndrome: unmasking an early diagnosis. Arch Neurol 2004, 6:1224-1229.
28. 123I beta CIT SPECT to assess serotonin transporters in vivo in humans: a double-blind, placebo-controlled, crossover study with the selective serotonin reuptake inhibitor citalopram. Neuropsychopharmacology 2005, 30:996-1005.
29. 123 I-FP-CIT SPECT is influenced by the selective serotonin reuptake inhibitor paroxetine: a double-blind, placebo-controlled, crossover study in healthy control subjects. J Nucl Med 2007, 48:359-366.
30. Tinazzi M., Ottaviani S., Isaias I.U., Pasquin I., Steinmayr M., Vampini C., et al. [123I] FP-CIT SPET imaging in drug-induced Parkinsonism. Mov Disord 2008, 23:1825-1829.
31. Schuurman A.G., van den Akker M., Ensinck K.T., Metsemakers J.F., Knottnerus J.A., Leentjens A.F., et al. Increased risk of Parkinson's disease after depression: a retrospective cohort study. Neurology 2002, 58:1501-1504.
32. Leentjens A.F., Van den Akker M., Metsemakers J.F., Lousberg R., Verhey F.R. Higher incidence of depression preceding the onset of Parkinson's disease: a register study. Mov Disord 2003, 18:414-418.